Biomedical Research Infrastructure Goes Global

Six institutions from Canada, the Czech Republic, Austria, France and Italy have now become official partners of the Infrafrontier consortium. With the participation of Canada, the consortium will be extended beyond Europe. The aim is to create a multinational research infrastructure for the phenotyping and archiving of mouse models of human diseases.

Helmholtz Zentrum München today announced that the Infrafrontier project, funded by the European Union, has been expanded to include six partners from Canada, the Czech Republic, Austria, France and Italy. The new partners will join the effort of the other 22 members of Infrafrontier in building up an international research infrastructure to improve open access to high-quality mouse models. Animal models have become an important tool in the study of complex human diseases such as diabetes, osteoporosis, asthma and depression, but also in the study of fundamental mechanisms such as speech development in humans. Colin McKerlie, spokesman of the Canadian partner, views the partnership as a "crucial step to successfully face one of the most interesting scientific challenges of the 21st century; to understand the function of every gene in the genome."

Professor Martin Hrabé de Angelis is director of the Institute of Experimental Genetics at Helmholtz Zentrum München and coordinates the EU Project Infrafrontier. "The international expansion facilitates the networking of the best scientists across the globe," Martin Hrabé de Angelis said. This opportunity is especially important to the Czech partners, as Prof. Radislav Sedlacek, programme coordinator for the Czech Center for Phenogenomics, stressed.

"We know that in the coming years we will be confronted with scientific tasks that cannot be solved with the infrastructure we currently have in Europe," Hrabé de Angelis went on to say. Infrafrontier will close this gap by expanding existing facilities and building new ones. A central coordination unit shall also be established. These endeavors will provide biomedical research with an international, open-access research infrastructure.

The partners in the Infrafrontier Consortium are the leading European systemic phenotyping centers (mouse clinics), the members of EMMA (European Mouse Mutant Archive) and research ministries and major funding agencies. New to Infrafrontier are the Czech Center for Phenogenomics and the Czech Republic's Ministry for Education, Youth and Sport, the Veterinary University of Vienna, the French institute INSERM (Institut National de la Santé et de la Recherche Médicale), the Italian Ministry of Labor, Health and Social Sciences and the Toronto Center for Phenogenomics. Altogether, 12 European countries and Canada now participate in Infrafrontier.

Infrafrontier is part of the ESFRI (European Strategy Forum on Research Infrastructures) roadmap, which outlines a plan to create research infrastructures of great scientific importance and pan-European interest, and which is therefore funded by the European Union.

For further information, please visit:
http://www.infrafrontier.eu

Most Popular Now

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...